Relmada Therapeutics, Inc. Stock News

CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc

Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint i

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer

Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) a

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD ) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. Unfortunately for RLMD stock, its RELIANCE III st

Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.

Shares of Relmada Therapeutics Inc. RLMD, -0.97% fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not me

100% technical buy signals. 8 new highs and up 15.55% in the last month.

We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid,

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer Jo

CORAL GABLES, Fla. , Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce

CORAL GABLES, Fla. , June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors, Investor Relations Sergio Traversa - Chief Execu

Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada Therapeutics reported quarterly